<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antipsychotics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="59/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int363-antipsychotics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="bnf_int363-antipsychotics.htm#pB" title="Skip Navigation">Skip Navigation</a><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int363-antipsychotics.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 06 Oct 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF September 2012</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int916-trospium.htm" title="Previous: Trospium">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1209-asenapine.htm" title="Next: Asenapine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1>Antipsychotics</h1><?highlighter on?><div id="pC" class="jN"><p><strong>Antipsychotics</strong> has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>ACE inhibitors</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>increased sedative effect when </span> <span>antipsychotics</span> <span>given with</span> <span>alcohol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>alpha-blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int555-amantadine.htm">Amantadine</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span> <span>antipsychotics</span> <span>given with</span> <span>amantadine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int39-anaesthetics-general.htm">Anaesthetics, General</a></td><td class="cAI"><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>general anaesthetics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="PHP8495-general-anaesthesia.htm#PHP8498">section 15.1</a>



</p></div></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int116-anti-arrhythmics.htm">Anti-arrhythmics</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>antipsychotics</span> <span>that prolong the QT interval given with</span> <span>anti-arrhythmics</span> <span>that prolong the QT interval</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>antipsychotics</span> <span>increase plasma concentration of</span> <span>tricyclics</span> <span>—possibly increased risk of ventricular arrhythmias</span>  </p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>antipsychotics</span> <span>antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int404-anxiolytics-and-hypnotics.htm">Anxiolytics and Hypnotics</a></td><td><p><span>increased sedative effect when </span> <span>antipsychotics</span> <span>given with</span> <span>anxiolytics and hypnotics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int430-apomorphine.htm">Apomorphine</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise effects of</span> <span>apomorphine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>antipsychotics</span> <span>that prolong the QT interval given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span> <span>antipsychotics</span> <span>advised by manufacturer of</span> <span>artemether/lumefantrine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>antipsychotics</span> <span>that prolong the QT interval given with</span> <span>atomoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int556-bromocriptine.htm">Bromocriptine</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise hypoprolactinaemic and antiparkinsonian effects of</span> <span>bromocriptine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int557-cabergoline.htm">Cabergoline</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise hypoprolactinaemic and antiparkinsonian effects of</span> <span>cabergoline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Dihydropyridine calcium-channel blockers include amlodipine, felodipine, isradipine, lacidipine, lercanidipine, nicardipine, nifedipine, and nimodipine</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>effects of </span> <span>antipsychotics</span> <span>possibly enhanced by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1180-histamine.htm">Histamine</a></td><td><p><span></span> <span>antipsychotics</span> <span>theoretically antagonise effects of</span> <span>histamine</span> <span>—manufacturer of <span>histamine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise effects of</span> <span>levodopa</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td><p><span>effects of </span> <span>antipsychotics</span> <span>possibly reduced by</span> <span>memantine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>antipsychotics</span> <span>that prolong the QT interval given with</span> <span>methadone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>enhanced hypotensive effect when </span> <span>antipsychotics</span> <span>given with</span> <span>methyldopa</span> <span>(also increased risk of extrapyramidal effects)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span> <span>antipsychotics</span> <span>given with</span> <span>metoclopramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td><p><span>enhanced hypotensive and sedative effects when </span> <span>antipsychotics</span> <span>given with</span> <span>opioid analgesics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int659-pergolide.htm">Pergolide</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise effects of</span> <span>pergolide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int881-pramipexole.htm">Pramipexole</a></td><td><p><span>avoidance of </span> <span>antipsychotics</span> <span>advised by manufacturer of</span> <span>pramipexole</span> <span>(antagonism of effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>antipsychotics</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int686-ropinirole.htm">Ropinirole</a></td><td><p><span>avoidance of </span> <span>antipsychotics</span> <span>advised by manufacturer of</span> <span>ropinirole</span> <span>(antagonism of effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1066-rotigotine.htm">Rotigotine</a></td><td><p><span>avoidance of </span> <span>antipsychotics</span> <span>advised by manufacturer of</span> <span>rotigotine</span> <span>(antagonism of effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1067-sodium-oxybate.htm">Sodium Oxybate</a></td><td><p><span></span> <span>antipsychotics</span> <span>possibly enhance effects of</span> <span>sodium oxybate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td><p><span></span> <span>antipsychotics</span> <span>antagonise hypertensive effect of</span> <span>sympathomimetics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int733-tetrabenazine.htm">Tetrabenazine</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span> <span>antipsychotics</span> <span>given with</span> <span>tetrabenazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td><p><span>increased risk of convulsions when </span> <span>antipsychotics</span> <span>given with</span> <span>tramadol</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Asenapine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of </span> <span>asenapine</span> <span>possibly increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span></span> <span>asenapine</span> <span>possibly increases plasma concentration of</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Paliperidone</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>plasma concentration of </span> <span>paliperidone</span> <span>reduced by</span> <span>carbamazepine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Aripiprazole</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>atazanavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>reduced by</span> <span>carbamazepine</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>efavirenz</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>fluoxetine</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>fosamprenavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>indinavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>itraconazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int298-ketoconazole.htm">Ketoconazole</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>inhibited by</span> <span>ketoconazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>lopinavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>nelfinavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int843-nevirapine.htm">Nevirapine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>nevirapine</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>paroxetine</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>phenytoin</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int200-rifabutin.htm">Rifabutin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>rifabutin</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>rifampicin</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>ritonavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>metabolism of </span> <span>aripiprazole</span> <span>possibly inhibited by</span> <span>saquinavir</span> <span>(reduce dose of <span>aripiprazole</span>)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>aripiprazole</span> <span>possibly reduced by</span> <span>St John's wort</span> <span>—increase dose of <span>aripiprazole</span></span>  </p></td><td></td></tr></tbody></table><p><strong>Amisulpride</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td class="cAI"><p><span>risk of ventricular arrhythmias with </span> <span>amisulpride</span> <span>increased by hypokalaemia caused by</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>erythromycin</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span>manufacturer of </span> <span>amisulpride</span> <span>advises avoid concomitant use of</span> <span>levodopa</span> <span>(antagonism of effect)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>methadone</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>pentamidine isetionate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>amisulpride</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Clozapine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>possible increased antimuscarinic side-effects when </span> <span>clozapine</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>clozapine</span> <span>given with</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td class="cAI"><p><span>serious adverse events reported with concomitant use of </span> <span>clozapine</span> <span>and</span> <span>benzodiazepines</span> <span>(causality not established)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span>metabolism of </span> <span>clozapine</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration), also avoid concomitant use of drugs with substantial potential for causing agranulocytosis</span>  </p></td><td></td></tr><tr><td><a href="bnf_int158-chloramphenicol.htm">Chloramphenicol</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with</span> <span>chloramphenicol</span> <span>(increased risk of agranulocytosis)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>effects of </span> <span>clozapine</span> <span>possibly enhanced by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>ciprofloxacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly increased by</span> <span>citalopram</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int500-cytotoxics.htm">Cytotoxics</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with</span> <span>cytotoxics</span> <span>(increased risk of agranulocytosis)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1072-deferasirox.htm">Deferasirox</a></td><td><p><span>avoidance of </span> <span>clozapine</span> <span>advised by manufacturer of</span> <span>deferasirox</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly increased by</span> <span>erythromycin</span> <span>(possible increased risk of convulsions)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span> <span>clozapine</span> <span>given with</span> <span>flecainide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int389-flupentixol.htm">Flupentixol</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>flupentixol</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr><tr><td><a href="bnf_int380-fluphenazine.htm">Fluphenazine</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>fluphenazine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>haloperidol</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects and possibly neurotoxicity when </span> <span>clozapine</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>clozapine</span> <span>possibly increases CNS effects of</span> <span>MAOIs</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly reduced by</span> <span>omeprazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>paroxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int658-penicillamine.htm">Penicillamine</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with</span> <span>penicillamine</span> <span>(increased risk of agranulocytosis)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly reduced by</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span> <span>clozapine</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int378-pipotiazine.htm">Pipotiazine</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>pipotiazine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly reduced by</span> <span>rifampicin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>risperidone</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>avoidance of </span> <span>clozapine</span> <span>advised by manufacturer of</span> <span>ritonavir</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>clozapine</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>sertraline</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int203-sulfonamides.htm">Sulfonamides</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with</span> <span>sulfonamides</span> <span>(increased risk of agranulocytosis)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>clozapine</span> <span>possibly increased or decreased by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>clozapine</span> <span>increased by</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int390-zuclopenthixol.htm">Zuclopenthixol</a></td><td class="cAI"><p><span>avoid concomitant use of </span> <span>clozapine</span> <span>with depot formulation of</span> <span>zuclopenthixol</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td></td></tr></tbody></table><p><strong>Olanzapine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td class="cAI"><p><span>increased risk of hypotension, bradycardia and respiratory depression when intramuscular</span> <span>olanzapine</span> <span>given with parenteral</span> <span>benzodiazepines</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span> <span>olanzapine</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span> <span>olanzapine</span> <span>possibly increased by</span> <span>ciprofloxacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of </span> <span>olanzapine</span> <span>increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>possible risk of toxicity when </span> <span>olanzapine</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span> <span>olanzapine</span> <span>reduced by</span> <span>ritonavir</span> <span>—consider increasing dose of <span>olanzapine</span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td class="cAI"><p><span>increased risk of side-effects including neutropenia when </span> <span>olanzapine</span> <span>given with</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Pimozide</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>SSRIs</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>tricyclics</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>imidazoles</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>triazoles</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1010-aprepitant.htm">Aprepitant</a></td><td class="cAI"><p><span>avoidance of </span> <span>pimozide</span> <span>advised by manufacturer of</span> <span>aprepitant</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>atazanavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>pimozide</span> <span>advised by manufacturer of</span> <span>boceprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>clarithromycin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td class="cAI"><p><span>risk of ventricular arrhythmias with </span> <span>pimozide</span> <span>increased by hypokalaemia caused by</span> <span>diuretics</span> <span>(avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int874-efavirenz.htm">Efavirenz</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>efavirenz</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>erythromycin</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>increased by</span> <span>fosamprenavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>indinavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1050-ivabradine.htm">Ivabradine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>ivabradine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1128-lapatinib.htm">Lapatinib</a></td><td class="cAI"><p><span>avoidance of </span> <span>pimozide</span> <span>advised by manufacturer of</span> <span>lapatinib</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>mefloquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>nelfinavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>phenothiazines</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>quinine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>increased by</span> <span>ritonavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>pimozide</span> <span>possibly increased by</span> <span>saquinavir</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>sulpiride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>avoidance of </span> <span>pimozide</span> <span>advised by manufacturer of</span> <span>telaprevir</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>telithromycin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>pimozide</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Quetiapine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int293-antifungals-imidazole.htm">Antifungals, Imidazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>imidazoles</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int300-antifungals-triazole.htm">Antifungals, Triazole</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>triazoles</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1005-atazanavir.htm">Atazanavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>atazanavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1214-boceprevir.htm">Boceprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>boceprevir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span> <span>quetiapine</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int168-clarithromycin.htm">Clarithromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>clarithromycin</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>darunavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>increased by</span> <span>erythromycin</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int1019-fosamprenavir.htm">Fosamprenavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>fosamprenavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Fosamprenavir is a prodrug of amprenavir</p></div></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int398-indinavir.htm">Indinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>indinavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int922-lopinavir.htm">Lopinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>lopinavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> In combination with ritonavir as Kaletra® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</p></div></td></tr><tr><td><a href="bnf_int842-nelfinavir.htm">Nelfinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>nelfinavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>metabolism of </span> <span>quetiapine</span> <span>accelerated by</span> <span>phenytoin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>ritonavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>saquinavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1216-telaprevir.htm">Telaprevir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>telaprevir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>telithromycin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1055-tipranavir.htm">Tipranavir</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>tipranavir</span> <span>—manufacturer of <span>quetiapine</span> advises avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int286-valproate.htm">Valproate</a></td><td><p><span>plasma concentration of </span> <span>quetiapine</span> <span>possibly increased by</span> <span>valproate</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Risperidone</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span> <span>risperidone</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>risperidone</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td><p><span>plasma concentration of </span> <span>risperidone</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>side-effects of </span> <span>risperidone</span> <span>possibly increased by</span> <span>methylphenidate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span>plasma concentration of </span> <span>risperidone</span> <span>possibly increased by</span> <span>paroxetine</span> <span>(increased risk of toxicity)</span>  </p></td><td></td></tr></tbody></table><p><strong>Sulpiride</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>amiodarone</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>sulpiride</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with parenteral</span> <span>erythromycin</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span> <span>sulpiride</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>pimozide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int755-sucralfate.htm">Sucralfate</a></td><td><p><span>absorption of </span> <span>sulpiride</span> <span>reduced by</span> <span>sucralfate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>sulpiride</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Phenothiazines</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int110-antacids.htm">Antacids</a></td><td><p><span>absorption of </span> <span>phenothiazines</span> <span>reduced by</span> <span>antacids</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</p></div></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>increased risk of antimuscarinic side-effects when </span> <span>phenothiazines</span> <span>given with</span> <span>tricyclics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>plasma concentration of </span> <span>phenothiazines</span> <span>reduced by</span> <span>antimuscarinics</span> <span>, but risk of antimuscarinic side-effects increased</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>beta-blockers</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>clonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>diazoxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>disopyramide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>diuretics</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1176-dronedarone.htm">Dronedarone</a></td><td class="cAI"><p><span>avoidance of </span> <span>phenothiazines</span> <span>advised by manufacturer of</span> <span>dronedarone</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>that prolong the QT interval given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>hydralazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int14-kaolin.htm">Kaolin</a></td><td><p><span>absorption of </span> <span>phenothiazines</span> <span>possibly reduced by</span> <span>kaolin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects and possibly neurotoxicity when </span> <span>phenothiazines</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>minoxidil</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>moxonidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>nitrates</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>pentamidine isetionate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span> <span>phenothiazines</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>phenothiazines</span> <span>given with</span> <span>sotalol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int268-sulfonylureas.htm">Sulfonylureas</a></td><td><p><span></span> <span>phenothiazines</span> <span>possibly antagonise hypoglycaemic effect of</span> <span>sulfonylureas</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Chlorpromazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>higher doses of </span> <span>chlorpromazine</span> <span>antagonise hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>effects of </span> <span>chlorpromazine</span> <span>possibly enhanced by</span> <span>cimetidine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int714-dexamfetamine.htm">Dexamfetamine</a></td><td><p><span>antipsychotic effects of </span> <span>chlorpromazine</span> <span>possibly antagonised by</span> <span>dexamfetamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>chlorpromazine</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of both drugs reduced when </span> <span>chlorpromazine</span> <span>given with</span> <span>phenobarbital</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span></span> <span>chlorpromazine</span> <span>possibly increases or decreases plasma concentration of</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td class="cAI"><p><span>plasma concentration of both drugs may increase when </span> <span>chlorpromazine</span> <span>given with</span> <span>propranolol</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>chlorpromazine</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Fluphenazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>fluphenazine</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr></tbody></table><p><strong>Levomepromazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int521-desferrioxamine.htm">Desferrioxamine</a></td><td><p><span>manufacturer of </span> <span>levomepromazine</span> <span>advises avoid concomitant use with</span> <span>desferrioxamine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Pericyazine</strong> belongs to <strong>Antipsychotics</strong> but has no specific interaction information.</p><p><strong>Perphenazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td><p><span>metabolism of </span> <span>perphenazine</span> <span>inhibited by</span> <span>paroxetine</span> <span>(reduce dose of <span>perphenazine</span>)</span>  </p></td><td></td></tr></tbody></table><p><strong>Pipotiazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>pipotiazine</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr></tbody></table><p><strong>Prochlorperazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int521-desferrioxamine.htm">Desferrioxamine</a></td><td><p><span>avoidance of </span> <span>prochlorperazine</span> <span>advised by manufacturer of</span> <span>desferrioxamine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Promazine</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int628-suxamethonium.htm">Suxamethonium</a></td><td><p><span></span> <span>promazine</span> <span>possibly enhances effects of</span> <span>suxamethonium</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Trifluoperazine</strong> belongs to <strong>Antipsychotics</strong> but has no specific interaction information.</p><p><strong>Butyrophenones</strong> belongs to <strong>Antipsychotics</strong> but has no specific interaction information.</p><p><strong>Droperidol</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>amisulpride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>tricyclics</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int335-chloroquine-and-hydroxychloroquine.htm">Chloroquine and Hydroxychloroquine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>chloroquine and hydroxychloroquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>fluoxetine</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>fluvoxamine</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>haloperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>macrolides</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> See also Telithromycin</p></div></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int808-pentamidine-isetionate.htm">Pentamidine Isetionate</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>pentamidine isetionate</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int373-phenothiazines.htm">Phenothiazines</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>phenothiazines</span> <span>that prolong the QT interval—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>pimozide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>quinine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>sertraline</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>droperidol</span> <span>given with</span> <span>sulpiride</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int730-tacrolimus.htm">Tacrolimus</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>tacrolimus</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="PHP7780-tacrolimus.htm">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</p></div></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td class="cAI"><p><span>manufacturer of </span> <span>droperidol</span> <span>advises avoid concomitant use with</span> <span>tamoxifen</span> <span>(risk of ventricular arrhythmias)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int42-thiopental.htm">Thiopental</a></td><td><p><span></span> <span>droperidol</span> <span>enhances effects of</span> <span>thiopental</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Benperidol</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>benperidol</span> <span>given with</span> <span>amiodarone</span> <span>—manufacturer of <span>benperidol</span> advises avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>benperidol</span> <span>given with</span> <span>moxifloxacin</span> <span>—manufacturer of <span>benperidol</span> advises avoid concomitant use</span>  </p></td><td></td></tr></tbody></table><p><strong>Haloperidol</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span></span> <span>haloperidol</span> <span>antagonises hypotensive effect of</span> <span>adrenergic neurone blockers</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>possibly increased by</span> <span>alprazolam</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>effects of </span> <span>haloperidol</span> <span>possibly reduced by</span> <span>antimuscarinics</span> <span></span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int1168-arsenic-trioxide.htm">Arsenic Trioxide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>arsenic trioxide</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int427-buspirone.htm">Buspirone</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>increased by</span> <span>buspirone</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td><p><span>metabolism of </span> <span>haloperidol</span> <span>accelerated by</span> <span>carbamazepine</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int374-chlorpromazine.htm">Chlorpromazine</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>possibly increased by</span> <span>chlorpromazine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>haloperidol</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>droperidol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>plasma concentration of </span> <span>haloperidol</span> <span>increased by</span> <span>fluoxetine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>possibly increased by</span> <span>fluvoxamine</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int70-indometacin.htm">Indometacin</a></td><td><p><span>possible severe drowsiness when </span> <span>haloperidol</span> <span>given with</span> <span>indometacin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int302-itraconazole.htm">Itraconazole</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>possibly increased by</span> <span>itraconazole</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects and possibly neurotoxicity when </span> <span>haloperidol</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int337-mefloquine.htm">Mefloquine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>mefloquine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>metabolism of </span> <span>haloperidol</span> <span>accelerated by</span> <span>phenobarbital</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>reduced by</span> <span>phenytoin</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>quinine</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int201-rifampicin.htm">Rifampicin</a></td><td class="cAI"><p><span>metabolism of </span> <span>haloperidol</span> <span>accelerated by</span> <span>rifampicin</span> <span>(reduced plasma concentration)</span>  </p></td><td></td></tr><tr><td><a href="bnf_int791-saquinavir.htm">Saquinavir</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>saquinavir</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1034-sodium-benzoate.htm">Sodium Benzoate</a></td><td><p><span></span> <span>haloperidol</span> <span>possibly reduces effects of</span> <span>sodium benzoate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1033-sodium-phenylbutyrate.htm">Sodium Phenylbutyrate</a></td><td><p><span></span> <span>haloperidol</span> <span>possibly reduces effects of</span> <span>sodium phenylbutyrate</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int371-sulpiride.htm">Sulpiride</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>sulpiride</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>haloperidol</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>plasma concentration of </span> <span>haloperidol</span> <span>increased by</span> <span>venlafaxine</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Thioxanthenes</strong> belongs to <strong>Antipsychotics</strong> but has no specific interaction information.</p><p><strong>Flupentixol</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>flupentixol</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects and possibly neurotoxicity when </span> <span>flupentixol</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr></tbody></table><p><strong>Zuclopenthixol</strong> belongs to <strong>Antipsychotics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int118-amiodarone.htm">Amiodarone</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with</span> <span>amiodarone</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</p></div></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span>avoid concomitant use of depot formulation of </span> <span>zuclopenthixol</span> <span>with</span> <span>clozapine</span> <span>as cannot be withdrawn quickly if neutropenia occurs</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int119-disopyramide.htm">Disopyramide</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with</span> <span>disopyramide</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with parenteral</span> <span>erythromycin</span> <span>—avoid concomitant use</span>  </p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td><p><span>increased risk of extrapyramidal side-effects and possibly neurotoxicity when </span> <span>zuclopenthixol</span> <span>given with</span> <span>lithium</span> <span></span>  </p></td><td></td></tr><tr><td><a href="bnf_int973-moxifloxacin.htm">Moxifloxacin</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with</span> <span>moxifloxacin</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int455-sotalol.htm">Sotalol</a></td><td class="cAI"><p><span>increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with</span> <span>sotalol</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr><tr><td><a href="bnf_int1227-vandetanib.htm">Vandetanib</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span> <span>zuclopenthixol</span> <span>given with</span> <span>vandetanib</span> <span>—avoid concomitant use</span>  </p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1209-asenapine.htm" title="Asenapine">Asenapine</a></li><li><a href="bnf_int1101-paliperidone.htm" title="Paliperidone">Paliperidone</a></li><li><a href="bnf_int1011-aripiprazole.htm" title="Aripiprazole">Aripiprazole</a></li><li><a href="bnf_int809-amisulpride.htm" title="Amisulpride">Amisulpride</a></li><li><a href="bnf_int364-clozapine.htm" title="Clozapine">Clozapine</a></li><li><a href="bnf_int366-olanzapine.htm" title="Olanzapine">Olanzapine</a></li><li><a href="bnf_int369-pimozide.htm" title="Pimozide">Pimozide</a></li><li><a href="bnf_int824-quetiapine.htm" title="Quetiapine">Quetiapine</a></li><li><a href="bnf_int368-risperidone.htm" title="Risperidone">Risperidone</a></li><li><a href="bnf_int371-sulpiride.htm" title="Sulpiride">Sulpiride</a></li><li id="_bnf_int373-phenothiazines"><a href="bnf_int373-phenothiazines.htm" title="Phenothiazines">Phenothiazines</a></li><li id="_bnf_int384-butyrophenones"><a href="bnf_int384-butyrophenones.htm" title="Butyrophenones">Butyrophenones</a></li><li id="_bnf_int388-thioxanthenes"><a href="bnf_int388-thioxanthenes.htm" title="Thioxanthenes">Thioxanthenes</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int916-trospium.htm">Previous: Trospium</a> | <a class="top" href="bnf_int363-antipsychotics.htm#">Top</a> | <a accesskey="]" href="bnf_int1209-asenapine.htm">Next: Asenapine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and Pharmaceutical Press 2012. All rights reserved. </a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>